S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
OTCMKTS:COTQF

Cotinga Pharmaceuticals Competitors

$0.08
-0.47 (-85.45 %)
(As of 01/14/2021 01:58 PM ET)
Add
Compare
Today's Range
$0.08
Now: $0.08
$0.61
50-Day Range
$0.03
MA: $0.21
$0.70
52-Week Range
$0.01
Now: $0.08
$0.95
Volume7,350 shs
Average Volume1,413 shs
Market Capitalization$1.76 million
P/E RatioN/A
Dividend YieldN/A
Beta43.44

Competitors

Cotinga Pharmaceuticals (OTCMKTS:COTQF) Vs. TRLPF, ABMC, RELV, PKPH, ICOTF, and ACUR

Should you be buying COTQF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cotinga Pharmaceuticals, including Acerus Pharmaceuticals (TRLPF), American Bio Medica (ABMC), Reliv' International (RELV), Peak Pharmaceuticals (PKPH), iCo Therapeutics (ICOTF), and Acura Pharmaceuticals (ACUR).

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, indicating that its stock price is 4,244% more volatile than the S&P 500.

Profitability

This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acerus Pharmaceuticals-254.66%-346.72%-94.54%
Cotinga PharmaceuticalsN/AN/AN/A

Institutional & Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acerus Pharmaceuticals and Cotinga Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acerus Pharmaceuticals0000N/A
Cotinga Pharmaceuticals0000N/A

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acerus Pharmaceuticals$7.38 million4.05$-18,790,000.00N/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Cotinga Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.

Summary

Cotinga Pharmaceuticals beats Acerus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for American Bio Medica and Cotinga Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
Cotinga Pharmaceuticals0000N/A

Earnings & Valuation

This table compares American Bio Medica and Cotinga Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million1.81$-680,000.00N/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Cotinga Pharmaceuticals.

Risk and Volatility

American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Profitability

This table compares American Bio Medica and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
Cotinga PharmaceuticalsN/AN/AN/A

Summary

Cotinga Pharmaceuticals beats American Bio Medica on 3 of the 5 factors compared between the two stocks.

Reliv' International (NASDAQ:RELV) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Earnings & Valuation

This table compares Reliv' International and Cotinga Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reliv' International$35.06 million0.19$-440,000.00N/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Reliv' International has higher revenue and earnings than Cotinga Pharmaceuticals.

Profitability

This table compares Reliv' International and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reliv' International-0.61%-1.89%-1.31%
Cotinga PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Reliv' International and Cotinga Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reliv' International0000N/A
Cotinga Pharmaceuticals0000N/A

Risk and Volatility

Reliv' International has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, meaning that its share price is 4,244% more volatile than the S&P 500.

Institutional and Insider Ownership

8.0% of Reliv' International shares are owned by institutional investors. 31.2% of Reliv' International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cotinga Pharmaceuticals beats Reliv' International on 5 of the 9 factors compared between the two stocks.

Cotinga Pharmaceuticals (OTCMKTS:COTQF) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cotinga Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cotinga Pharmaceuticals0000N/A
Peak Pharmaceuticals0000N/A

Earnings & Valuation

This table compares Cotinga Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Volatility and Risk

Cotinga Pharmaceuticals has a beta of 43.44, indicating that its share price is 4,244% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of -0.91, indicating that its share price is 191% less volatile than the S&P 500.

Profitability

This table compares Cotinga Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cotinga PharmaceuticalsN/AN/AN/A
Peak PharmaceuticalsN/AN/AN/A

Summary

Cotinga Pharmaceuticals beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

iCo Therapeutics (OTCMKTS:ICOTF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares iCo Therapeutics and Cotinga Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iCo TherapeuticsN/AN/A$-1,460,000.00N/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Profitability

This table compares iCo Therapeutics and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iCo TherapeuticsN/A-472.87%-177.94%
Cotinga PharmaceuticalsN/AN/AN/A

Volatility & Risk

iCo Therapeutics has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, indicating that its share price is 4,244% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for iCo Therapeutics and Cotinga Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iCo Therapeutics0000N/A
Cotinga Pharmaceuticals0000N/A

Summary

Cotinga Pharmaceuticals beats iCo Therapeutics on 4 of the 5 factors compared between the two stocks.

Acura Pharmaceuticals (OTCMKTS:ACUR) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Acura Pharmaceuticals and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acura Pharmaceuticals-19.89%-1.36%-34.83%
Cotinga PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Acura Pharmaceuticals and Cotinga Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acura Pharmaceuticals$2.66 million1.79N/AN/AN/A
Cotinga PharmaceuticalsN/AN/A$-2,050,000.00N/AN/A

Acura Pharmaceuticals has higher revenue and earnings than Cotinga Pharmaceuticals.

Volatility & Risk

Acura Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acura Pharmaceuticals and Cotinga Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acura Pharmaceuticals0000N/A
Cotinga Pharmaceuticals0000N/A

Summary

Cotinga Pharmaceuticals beats Acura Pharmaceuticals on 5 of the 6 factors compared between the two stocks.


Cotinga Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.12-3.9%$6.83 million$7.38 million0.00High Trading Volume
ABMC
American Bio Medica
0.5$0.18-14.0%$6.60 million$3.65 million0.00High Trading Volume
RELV
Reliv' International
0.7$3.72-14.7%$6.49 million$35.06 million-33.77High Trading Volume
Increase in Short Interest
Heavy News Reporting
PKPH
Peak Pharmaceuticals
0.7$0.08-1.3%$5.96 millionN/A0.00
ICOTF
iCo Therapeutics
0.5$0.04-4.7%$5.92 millionN/A-1.93
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.22-4.5%$4.77 million$2.66 million-7.34
ISCO
International Stem Cell
0.8$0.52-3.8%$4.07 million$9.47 million0.00
WIZP
Wize Pharma
0.6$0.24-2.8%$4.00 millionN/A-0.54
Innovus Pharmaceuticals logo
INNV
Innovus Pharmaceuticals
0.5$1.23-5.7%$3.94 million$23.99 million-0.38
BNTC
Benitec Biopharma
1.2$3.55-2.8%$3.93 million$100,000.00-0.44
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.16-3.0%$3.74 million$3.48 million-1.35Increase in Short Interest
AMBS
Amarantus BioScience
0.0$0.01-4.8%$3.10 millionN/A0.00
INNVD
Innovus Pharmaceuticals
0.6$3.00-59.0%$2.90 million$23.99 million-0.72
PVTTF
Pivotal Therapeutics
0.6$0.03-0.0%$2.76 millionN/A0.00
CAPS
Capstone Therapeutics
0.8$34.00-5.9%$2.72 million$2 million0.00
BTHE
Boston Therapeutics
0.5$0.02-24.5%$2.40 million$20,000.00-1.08
MLNTQ
Melinta Therapeutics
0.2$0.11-7.9%$1.51 million$96.43 million0.00
VGLS
VG Life Sciences
0.0$0.01-20.4%$1.27 millionN/A0.00
ETST
Earth Science Tech
0.5$0.03-13.9%$1.25 million$530,000.000.00
NSPX
Inspyr Therapeutics
0.5$0.01-2.9%$1.11 millionN/A0.00
STLT
Spotlight Innovation
0.5$0.02-0.0%$754,000.00N/A0.00
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.02-1.7%$594,000.00N/A0.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
AKAOQ
Achaogen
0.6$0.01-8.6%$540,000.00$8.73 million0.00
SPHS
Sophiris Bio
0.3$0.01-13.5%$501,000.00N/A0.00
PPCB
Propanc Biopharma
0.7$0.26-11.5%$453,000.00N/A0.00
HSTC
HST Global
0.8$0.09-5.8%$451,000.00N/A0.00
PXYN
Praxsyn
0.6$0.00-0.0%$339,000.00N/A0.00
TRGM
Targeted Medical Pharma
0.8$0.01-30.4%$339,000.00N/A0.00High Trading Volume
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00
SKVI
Skinvisible
0.7$0.07-79.2%$291,000.00$40,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
IMUN
Immune Therapeutics
0.6$0.02-2.4%$10,000.00$110,000.000.00
NEVPF
Abliva AB (publ)
0.5$0.08-24.4%$0.00$10,000.00-1.60
AOLS
Aeolus Pharmaceuticals
0.8$0.00-0.0%$0.00N/A0.00
Affymax logo
AFFY
Affymax
0.6$0.11-8.9%$0.00N/A0.00Increase in Short Interest
AOBI
American Oriental Bioengineering
0.4$4.95-0.0%$0.00N/A0.00
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.04-2.4%$0.00N/A0.00
AOXG
Aoxing Pharmaceutical
0.5$0.01-19.7%$0.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-21.4%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-14.3%$0.00N/A0.00
FWDG
FutureWorld
0.5$0.00-0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.05-1.8%$0.00N/A0.00High Trading Volume
GBIM
GlobeImmune
0.5$0.25-7.1%$0.00N/A0.00
Intec Pharma logo
NTEC
Intec Pharma
1.4$4.13-5.1%$0.00N/A-0.58
MBVXQ
MabVax Therapeutics
0.0$0.02-8.7%$0.00N/A0.00
MYRX
Myrexis
0.5$0.03-11.8%$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.05-20.6%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00-100.0%$0.00N/A0.00
This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.